These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
183 related items for PubMed ID: 8836892
21. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. McGuinness PH, Bishop GA, Painter DM, Chan R, McCaughan GW. Hepatology; 1996 Apr; 23(4):676-87. PubMed ID: 8666317 [Abstract] [Full Text] [Related]
23. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone. Scotto G, Fazio V, Tantimonaco G. Ital J Gastroenterol; 1996 Dec; 28(9):505-11. PubMed ID: 9131395 [Abstract] [Full Text] [Related]
29. Detection of anti-HCV IgM antibodies in patients with chronic hepatitis C treated with interferon. Picciotto A, Icardi G, Bardellini E, Borro P, Borzone S, Pireddu M, Sinelli N, Pezzano D, Orione L, Di Giacomo C. Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):623-5. PubMed ID: 8590156 [Abstract] [Full Text] [Related]
30. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Kakehashi R, Kaito M, Kondo M, Hayashi Y, Jomori T, Suzuki S. Hepatology; 1993 Dec; 18(6):1319-25. PubMed ID: 8244255 [Abstract] [Full Text] [Related]
33. Effectiveness of relative low-dose interferon treatment for patients with chronic hepatitis C. Hayashi J, Kishihara Y, Tani Y, Yamaji K, Nakashima K, Ikematsu H, Kashiwagi S. Fukuoka Igaku Zasshi; 1994 Jul; 85(7):211-8. PubMed ID: 8070751 [Abstract] [Full Text] [Related]
34. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. Hepatology; 1996 Apr; 23(4):695-9. PubMed ID: 8666319 [Abstract] [Full Text] [Related]
37. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Roffi L, Mels GC, Antonelli G, Bellati G, Panizzuti F, Piperno A, Pozzi M, Ravizza D, Angeli G, Dianzani F. Hepatology; 1995 Mar; 21(3):645-9. PubMed ID: 7875661 [Abstract] [Full Text] [Related]
38. [Long-term treatment of cryptogenic hepatitis C using recombinant interferon alpha]. Hopf U, Möller B, König V, Küther S, Lobeck H, Huhn D. Z Gastroenterol; 1990 Sep; 28(9):453-7. PubMed ID: 2125776 [Abstract] [Full Text] [Related]
39. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y. Hepatology; 1995 Feb; 21(2):291-7. PubMed ID: 7843696 [Abstract] [Full Text] [Related]